

Table S1: Hazard Ratios of Survival Studies			
Immune Checkpoint Therapy Experiments			
	NT	aPD1/aCTLA4	Model
Hazard Ratio (logrank)	0.7413	1.349	T11 Parent
95% CI of ratio	0.3772 to 1.457	0.6863 to 2.651	
Hazard Ratio (logrank)	6.817	0.1467	T11-Apobec
95% CI of ratio	2.481 to 18.74	0.05338 to 0.4031	
Hazard Ratio (logrank)	5.326	0.1877	T11uv
95% CI of ratio	1.764 to 16.08	0.06219 to 0.5667	
Hazard Ratio (logrank)	2.126	0.4703	KPB25L Parent
95% CI of ratio	1.012 to 4.47	0.2237 to 0.9886	
Hazard Ratio (logrank)	4.96	0.2016	KPB25Luv
95% CI of ratio	2.281 to 10.79	0.09268 to 0.4385	
Hazard Ratio (logrank)	4.199	0.2381	KPB25L-Apobec
95% CI of ratio	1.471 to 11.99	0.08343 to 0.6797	
Hazard Ratio (logrank)	0.753	1.328	2153L
95% CI of ratio	0.3844 to 1.475	0.6781 to 2.601	
Hazard Ratio (logrank)	1.347	0.7425	2225L
95% CI of ratio	0.6674 to 2.718	0.3679 to 1.498	
Hazard Ratio (logrank)	0.9969	1.003	2336R
95% CI of ratio	0.5581 to 1.781	0.5616 to 1.792	
Hazard Ratio (logrank)	1.267	0.7895	2224L
95% CI of ratio	0.6986 to 2.297	0.4354 to 1.431	
Hazard Ratio (logrank)	1.103	0.9067	9263-3F
95% CI of ratio	0.4008 to 3.035	0.3295 to 2.495	
	NT	aPD1	
Hazard Ratio (logrank)	2.972	0.3365	T11-Apobec
95% CI of ratio	1.377 to 6.415	0.1559 to 0.7265	
Ratio (and its reciprocal)	3.054	0.3274	KPB25Luv
95% CI of ratio	1.484 to 6.289	0.159 to 0.6741	
	NT	aCTLA4	
Hazard Ratio (logrank)	3.824	0.2615	T11-Apobec
95% CI of ratio	1.76 to 8.307	0.1204 to 0.5682	
Ratio (and its reciprocal)	2.452	0.4079	KPB25Luv
95% CI of ratio	1.183 to 5.079	0.1969 to 0.845	
Immune Cell Depletion/Inhibition Experiments			
	aPD1/aCTLA4	aCD19/aPD1/aCTLA4	
Hazard Ratio (logrank)	0.2494	4.009	T11-Apobec
95% CI of ratio	0.09804 to 0.6347	1.576 to 10.2	
Hazard Ratio (logrank)	0.2492	4.012	KPB25Luv
95% CI of ratio	0.09158 to 0.6782	1.474 to 10.92	
	aPD1/aCTLA4	aCD20/aPD1/aCTLA4	
Hazard Ratio (logrank)	0.2887	3.463	T11-Apobec
95% CI of ratio	0.09039 to 0.9223	1.084 to 11.06	
Hazard Ratio (logrank)	0.2276	4.394	KPB25Luv
95% CI of ratio	0.08854 to 0.585	1.71 to 11.29	
	aPD1/aCTLA4	aCD8/aPD1/aCTLA4	
Hazard Ratio (logrank)	0.498	2.008	T11-Apobec
95% CI of ratio	0.2464 to 1.006	0.9939 to 4.058	
Hazard Ratio (logrank)	0.3428	2.917	KPB25Luv
95% CI of ratio	0.1464 to 0.8028	1.246 to 6.831	
	aPD1/aCTLA4	aCD4/aPD1/aCTLA4	
Hazard Ratio (logrank)	0.09922	10.08	T11-Apobec
95% CI of ratio	0.01952 to 0.5043	1.983 to 51.22	
Hazard Ratio (logrank)	0.1288	7.763	KPB25Luv
95% CI of ratio	0.03407 to 0.4869	2.054 to 29.35	
	aPD1/aCTLA4	aL21/aPD1/aCTLA4	
Hazard Ratio (logrank)	0.3799	2.633	T11-Apobec
95% CI of ratio	0.1417 to 1.018	0.982 to 7.058	
Ratio (and its reciprocal)	0.1556	6.428	KPB25Luv
95% CI of ratio	0.03465 to 0.6987	1.431 to 28.86	
	aPD1/aCTLA4	Igmi aPD1/aCTLA4	
Hazard Ratio (logrank)	0.2056	4.863	T11-Apobec
95% CI of ratio	0.0438 to 0.9653	1.036 to 22.83	
	aPD1/aCTLA4	aCD16/aPD1/aCTLA4	
Hazard Ratio (logrank)	0.4293	2.329	KPB25Luv
95% CI of ratio	0.1946 to 0.9471	1.056 to 5.139	
	NT	Isotype controls	
Hazard Ratio (logrank)	1.144	0.8739	T11-Apobec
95% CI of ratio	0.5267 to 2.486	0.4023 to 1.898	
Hazard Ratio (logrank)	0.8905	1.123	KPB25L
95% CI of ratio	0.4025 to 1.97	0.5075 to 2.485	